The Conversation (0)
HEXO (TSX:HEXO,NYSE:HEXO) announced on Monday (October 28) it received a research license for its Belleville, Ontario facility and licenses for the sale of cannabis-infused topicals, extracts, edibles and beverages from its flagship Gatineau campus. As quoted in the press release: “The research licence will allow us to take our innovation work to the next level, …
HEXO (TSX:HEXO,NYSE:HEXO) announced on Monday (October 28) it received a research license for its Belleville, Ontario facility and licenses for the sale of cannabis-infused topicals, extracts, edibles and beverages from its flagship Gatineau campus.
As quoted in the press release:
“The research licence will allow us to take our innovation work to the next level, with testing on derivative products, including taste testing. Consumers have high expectations for their packaged goods experiences, and cannabis will be no different,” said Sebastien St-Louis, CEO and co-founder of HEXO Corp. “We are committed to not only ensuring a quality consistent experience but to also guaranteeing that experiences powered by HEXO meet these expectations.”
While a Processing Licence provides for testing on live plants, fresh and dried plant material, seeds, and oil, a Research and Development Licence significantly expands the scope of work that can be conducted on cannabis and its derivatives. The Company plans to conduct research and development at its Vaughan and Montreal Innovation, Development and Engineering hubs, as well as at its Centre of Excellence in Belleville and in other facilities.